1. Home
  2. EWTX vs PBI Comparison

EWTX vs PBI Comparison

Compare EWTX & PBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edgewise Therapeutics Inc.

EWTX

Edgewise Therapeutics Inc.

HOLD

Current Price

$23.83

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Pitney Bowes Inc.

PBI

Pitney Bowes Inc.

HOLD

Current Price

$9.91

Market Cap

1.6B

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
EWTX
PBI
Founded
2017
1920
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Office Equipment/Supplies/Services
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
EWTX
PBI
Price
$23.83
$9.91
Analyst Decision
Buy
Buy
Analyst Count
10
2
Target Price
$37.30
$12.00
AVG Volume (30 Days)
1.3M
2.9M
Earning Date
11-06-2025
10-29-2025
Dividend Yield
N/A
3.23%
EPS Growth
N/A
N/A
EPS
N/A
0.45
Revenue
N/A
$1,931,125,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$22.07
Revenue Growth
N/A
N/A
52 Week Low
$10.60
$6.88
52 Week High
$35.50
$13.11

Technical Indicators

Market Signals
Indicator
EWTX
PBI
Relative Strength Index (RSI) 62.17 49.79
Support Level $22.51 $9.45
Resistance Level $26.30 $10.08
Average True Range (ATR) 1.46 0.26
MACD -0.10 0.11
Stochastic Oscillator 60.17 84.07

Price Performance

Historical Comparison
EWTX
PBI

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About PBI Pitney Bowes Inc.

Pitney Bowes Inc is a technology-driven company that provides SaaS shipping solutions, mailing innovation, and financial services to clients around the globe. The company's reportable segments are SendTech Solutions and Presort Services. SendTech Solutions includes the revenue and related expenses from physical and digital mailing and shipping technology solutions, financing, services, supplies and other applications to help simplify and save on the sending, tracking and receiving of letters, parcels and flats. Presort Services includes the revenue and related expenses from sortation services to qualify large volumes of First Class Mail, Marketing Mail and Marketing Mail Flats/Bound Printed Matter for postal worksharing discounts. It derives maximum revenue from SendTech Solutions.

Share on Social Networks: